Table 2 Adverse Events Reported in ≥2% of Patients During Open-Label Treatment With Lurasidone
Adverse Event, n (%) | LUR-LURa (N = 136) | RIS-LURb (N = 87) |
|---|---|---|
≥1 adverse event | 80 (58.8) | 51 (58.6) |
Headache | 7 (5.1) | 7 (8.0) |
Psychotic disorder | 6 (4.4) | 6 (6.9) |
Parkinsonism | 5 (3.7) | 5 (5.7) |
Anxiety | 2 (1.5) | 6 (6.9) |
Blood creatine phosphokinase increased | 5 (3.7) | 3 (3.4) |
Insomnia | 3 (2.2) | 5 (5.7) |
Nasopharyngitis | 5 (3.7) | 3 (3.4) |
Akathisia | 5 (3.7) | 2 (2.3) |
Somnolence | 5 (3.7) | 2 (2.3) |
Influenza | 6 (4.4) | 1 (1.1) |
Nausea | 3 (2.2) | 3 (3.4) |
Upper respiratory infection | 6 (4.4) | 0 (0) |
Vomiting | 3 (2.2) | 3 (3.4) |
Back pain | 2 (1.5) | 3 (3.4) |
Decreased appetite | 3 (2.2) | 2 (2.3) |
Weight decreased | 4 (2.9) | 1 (1.1) |